Liver cancer trial halted: drug combo vs. standard therapy
NCT ID NCT04777851
First seen Mar 24, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study aimed to see if a combination of two drugs (regorafenib and pembrolizumab) worked better than standard treatments (TACE or TARE) for people with intermediate-stage liver cancer. The trial was planned for about 496 participants but was stopped early, so only limited data is available. The goal was to slow cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Edegem, 2650, Belgium
-
CHU Amiens-Picardie
Amiens, 80054, France
-
Center of Oncology Euroclinic Victoria Hospital
Iași, 700106, Romania
-
Cha Bundang Medical Center
Seongnam-si, South Korea
-
Chang Gung Memorial Hospital - Linkou
Taoyuan, 333, Taiwan
-
Clinic for Digestive Surgery, University Clinical Center of Serbia
Belgrade, Serbia
-
Gazi University MF
Ankara, 6560, Turkey (Türkiye)
-
Gülhane Eğitim ve Araştırma Hastanesi
Ankara, 6010, Turkey (Türkiye)
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Humanity and Health Clinical Trial Center
Hong Kong, 999077, Hong Kong
-
Hôpital Beaujon - APHP
Clichy, 92110, France
-
Hôpital Henri Mondor
Créteil, 94010, France
-
Inje University Haeundae Paik Hospital
Busan, South Korea
-
Institue of Oncology Vojvodine Sremska Kamenica (Oncology Institute of Volvodina)
Kamenitz, 21204, Serbia
-
Institutul Clinic Fundeni
Bucharest, 22328, Romania
-
Israel-Georgian Medical Research Clinic Healthycore
Tbilisi, 0112, Georgia
-
JSC VIANI Batumi Referral Hospital
Batumi, 6010, Georgia
-
Koc University Hospital
Istanbul, 34010, Turkey (Türkiye)
-
National Taiwan University Hospital
Taipei, 10041, Taiwan
-
Ospedale Garibaldi Nesima
Catania, 95122, Italy
-
Regional Institute of Gastroenterology and Hepatology "Dr Octavian Fodor"
Cluj-Napoca, 400394, Romania
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
UCL SAINT LUC - UC Louvain
Brussels, 1200, Belgium
-
UCLA Santa Monica Hematology Oncology
Santa Monica, California, 90404, United States
-
Universitätsmedizin: Medizinische Klinik und Poliklinik I
Mainz, D-55131, Germany
Conditions
Explore the condition pages connected to this study.